Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • EELS (Ethical Economic Legal and Social) Article
  • Published:

EELS

Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees

The Pharmacogenomics Journal volume 9, pages 86–89 (2009)Cite this article

Abstract

The decision taken by research ethics committees (RECs) while assessing pharmacogenetic (PGx) substudies as part of international clinical trials is almost unknown. A total of 255 applications of 36 PGx substudies embedded in clinical trials (12 phase 2, 24 phase 3) were submitted to 72 RECs in 2006–2007 by GlaxoSmithKline in Spain. These were trials of 17 different compounds, aimed to be conducted in the five continents. Of the 255 applications, 226 (89%) were directly approved by RECs without raising any queries to the sponsor; 1% (3/255) were plainly rejected by two RECs. The rest (10%) were followed by 64 queries asked by 16 RECs on 25 PGx substudies. Following responses from the sponsor, all but two applications were approved. Thus, the RECs involved finally approved 98% (250/255) of the submitted applications. The requirements specifically raised by two RECs (PGx samples to be transferred to a public biobank or alternatively destroyed immediately, or storage permitted only 5 years after the trial is concluded) could not be met by the sponsor. It can be inferred from the results obtained that ethical and scientific standards implemented by the sponsor in the design, conduct and sample management of PGx substudies satisfied the vast majority (70/72; 97%) of RECs involved in this study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Relling MV, Hoffman JM . Should pharmacogenomic studies be required for new drug approval? Clin Pharmacol Ther 2007; 81: 425–428.

    Article  CAS  PubMed  Google Scholar 

  2. SACGHS Secretary's Advisory Committee on Genetics, Health, and Society. Realizing the Promise of Pharmacogenomics: Opportunities and Challenges, May 2008 [Accessed 20 August 2008]. Available at http://www4.od.nih.gov/oba/SACGHS/reports/SACGHS_PGx_Report.pdf.

  3. Roses AD . Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008; 7: 807–817.

    Article  CAS  PubMed  Google Scholar 

  4. Ingelman-Sundberg M . Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008; 358: 637–639.

    Article  CAS  PubMed  Google Scholar 

  5. European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP). Position paper on terminology in pharmacogenetics. EMEA/CPMP/3070/01. London, 21 November 2002. [Accessed on 18 August 2008]. Available at http://www.emea.europa.eu/pdfs/human/press/pp/307001en.pdf.

  6. European Medicines Agency. ICH Topic E15. Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. EMEA/CHMP/ICH/437986/2006. London, November 2007. [Accessed on 18 August 2008]. Available at http://www.emea.europa.eu/pdfs/human/ich/43798606en.pdf.

  7. US Department of Health and Human Services. Food and Drug Administration. Guidance for industry. Pharmacogenomic data submissions. March 2005. [Accessed on 19 August 2008] Available at http://www.fda.gov/cder/guidance/6400fnl.pdf.

  8. US Department of Health and Human Services. Food and Drug Administration. Guidance for industry and FDA staff. Pharmacogenetic tests and genetic tests for heritable markers. [Accessed on 2 September 2008] Available at http://www.fda.gov/cdrh/oivd/guidance/1549.pdf.

  9. Council for International Organizations of Medical Sciences (CIOMS). Pharmacogenetics: towards improving treatments with medicines. 2005. Geneva, Switzerland. [Accessed on 2 September 2008] Available at http://www.cioms.ch/frame_pharmacogenetics_febr_2005.htm.

  10. Nuffield Council on Bioethics. Pharmacogenetics: ethical issues. September 2003. [Accessed on 20 August 2008]. Available at http://www.nuffieldbioethics.org/fileLibrary/pdf/pharmacogenetics_report.pdf.

  11. Rodríguez-Villanueva J, Alsar MJ, Avendaño C, Gómez-Piqueras C, Garcia-Alonso F . Pharmacogenetic studies: evaluation guidelines for research ethics committees. Scientific background and legal framework. (I). Med Clín (Barc) 2003; 120: 63–67, [in Spanish].

    Article  Google Scholar 

  12. Rodríguez-Villanueva J, Alsar MJ, Avendaño C, Gómez-Piqueras C, Garcia-Alonso F . Pharmacogenetic studies: evaluation guidelines for research ethics committees. Study protocol and patient information sheet (II). Med Clin (Barc) 2003; 120: 101–107, [in Spanish].

    Article  Google Scholar 

  13. Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H . Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 2004; 5: 676–677.

    Article  CAS  PubMed  Google Scholar 

  14. Directive 2001/20/CE of the European Parliament and the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Commun 2001; L121: 34–44.

  15. Burman WJ, Reves RR, Cohn DL, Schooley RT . Breaking the camel's back: multicenter clinical trials and local institutional review boards. Ann Intern Med 2001; 134: 152–157.

    Article  CAS  PubMed  Google Scholar 

  16. Keinonen T, Nieminen S, Saareks V, Saano V, Ylitalo P . Acceptability and profile of the clinical drug trials underway in Finnish university hospitals in the 1990s: Applications reviewed by ethics committees. Methods Find Exp Clin Pharmacol 2001; 23: 415–423.

    Article  CAS  PubMed  Google Scholar 

  17. Dal-Ré R, Ortega R, Morejón E . Multicentre trials review process by research ethics committees in Spain: where do they stand before implementing the new European regulation? J Med Ethics 2005; 31: 744–750.

    Article  Google Scholar 

  18. Angell E, Sutton AJ, Windridge K, Dixon-Woods M . Consistency in decision making by research ethics committees: a controlled comparison. J Med Ethics 2006; 32: 662–664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Edwards SJ, Stone T, Swift T . Differences between research ethics committees. Int J Technol Assess Health Care 2007; 23: 17–23.

    Article  PubMed  Google Scholar 

  20. Lambers Heerspink H, Dobre D, Hillege HL, Grobbe DE, Zeeuw D, for the Collaborative Study Group. Does the European clinical trials directive really improve clinical trial approval time? Br J Clin Pharmacol 2008; 66: 546–550.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Arledge T, Freeman A, Arbuckle J, Mosteller M, Manasco P . Applications of phamacogenetics to drug development: the Glaxo Wellcome experience. Drug Metab Rev 2000; 32: 387–394.

    Article  CAS  PubMed  Google Scholar 

  22. Levine RJ . Ethics and Regulation of Clinical Research. 2nd ed. Urban & Schwarzenberg: Baltimore, 1986.

    Google Scholar 

  23. Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, Switzerland., 2002.

  24. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568–579.

    Article  PubMed  Google Scholar 

  25. Hughes AR, Spreen WR, Mosteller M, Warren LL, Lai EH, Brothers CH et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 2008; 8: 365–374.

    Article  CAS  PubMed  Google Scholar 

  26. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121–1122.

    Article  CAS  PubMed  Google Scholar 

  27. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54–59.

    Article  CAS  PubMed  Google Scholar 

  28. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563–2570.

    Article  CAS  PubMed  Google Scholar 

  29. Lesko LJ . The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 2008; 84: 301–303.

    Article  CAS  PubMed  Google Scholar 

  30. Garcia DA . Warfarin and pharmacogenomic testing: the case for restraint. Clin Pharmacol Ther 2008; 84: 303–306.

    Article  CAS  PubMed  Google Scholar 

  31. Ley 14/2007 de 3 de julio, de Investigación Biomédica. BOE n° 159, de 4 de julio de 2007: 28826–28848.

Download references

Author information

Authors and Affiliations

  1. Medical Department, GlaxoSmithKline SA, Tres Cantos, Madrid, Spain

    R Dal-Ré, I Luque, R Torres & J Lahuerta

Authors
  1. R Dal-Ré
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Luque
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Lahuerta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Dal-Ré.

Additional information

Duality of interest

The authors work at GlaxoSmithKline SA, Tres Cantos, Madrid, Spain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dal-Ré, R., Luque, I., Torres, R. et al. Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees. Pharmacogenomics J 9, 86–89 (2009). https://doi.org/10.1038/tpj.2008.18

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2008.18

Keywords

This article is cited by

Search

Advanced search

Quick links